Pablo Cagnoni

Pablo Cagnoni, M.D., has led the development, approval, and/or commercialization of more than twenty approved medicines. He is currently the CEO of Rubius Therapeutics, a clinical-stage biotech company developing genetically engineered red blood cells to treat various cancers and autoimmune diseases. Prior to Rubius, Dr. Cagnoni served as the President and CEO of Tizona Therapeutics. Previously, he was President of Onyx Pharmaceuticals (acquired by Amgen), where he led efforts from early product development to commercialization of the full portfolio. Dr. Cagnoni has had several clinical development leadership roles in his past, including Global Head of Clinical Development at Novartis Oncology, CMO at Allos Therapeutics, and CMO at OSI Pharmaceuticals.